RT Journal Article
SR Electronic
T1 Beyond Deaths per Capita: Comparative CoViD-19 Mortality Indicators
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.04.29.20085506
DO 10.1101/2020.04.29.20085506
A1 Heuveline, Patrick
A1 Tzen, Michael
YR 2021
UL http://medrxiv.org/content/early/2021/01/12/2020.04.29.20085506.abstract
AB Objectives Following well-established practices in demography, this article discusses several measures based on the number of CoViD-19 deaths to facilitate comparisons over time and across populations.Settings National populations in 186 UN countries and territories and populations in first-level sub-national administrative entities in Brazil, China, Italy, Mexico, Peru, Spain, and the USA.Participants None (death statistics only).Primary and Secondary Outcome Measures An unstandardized occurrence/exposure rate comparable to the Crude Death Rate; an indirectly age-and-sex standardized rate that can be derived even when the breakdown of CoViD-19 deaths by age and sex required for direct standardization is unavailable; the reduction in life expectancy at birth corresponding to the 2020 number of CoViD-19 deaths.Results To date, the highest unstandardized rate has been in New York, at its peak exceeding the state 2017 Crude Death Rate. Populations compare differently after standardization: while parts of Italy, Spain and the USA have the highest unstandardized rates, parts of Mexico and Peru have the highest standardized rates. For several populations with the necessary data by age and sex for direct standardization, we show that direct and indirect standardization yield similar results. US life expectancy is estimated to have declined this year by more than a year (−1.26 years), far more than during the worst year of the HIV epidemic, or the worst three years of the opioid crisis, and to reach its lowest level since 2008. Substantially larger reductions, exceeding two years, are estimated for Panama, Peru, and parts of Italy, Spain, the USA, and especially, Mexico.Conclusions With lesser demand on data than direct standardization, indirect standardization is a valid alternative to adjust international comparisons for differences in population distribution by sex and age-groups. A number of populations have experienced reductions in 2020 life expectancies that are substantial by recent historical standards.Strengths and limitationsThe CoViD-19 mortality indicators presented in this article are directly comparable with three well-established indicators of overall mortality: the Crude Death Rate, the Age-Standardized Death Rate and Life Expectancy at BirthIn particular, this article demonstrates that when CoViD-19 deaths in a population are not tabulated by sex and age, indirect standardization techniques can still be used to improve comparisons of CoViD-19 mortality in this and other populations by accounting for differences in population distributions by age and sexWhile requiring additional data on mortality from other causes, translating cumulative numbers of CoViD-19 deaths into their impact on life expectancy at birth allows for comparison of CoViD-19 mortality with previous reversals in secular mortality declinesThe comparability of these CoViD-19 mortality indicators is affected by potential differences in identifying and reporting CoViD-19 as a cause of death across populationsFurther analyses are needed to assess potential changes in mortality from other causes induced by CoViD-19, as those would also contribute to the impact of CoViD-19 on life expectancy at birthCompeting Interest StatementThe authors have declared no competing interest.Funding StatementThe authors benefited from facilities and resources provided by the California Center for Population Research at UCLA (CCPR), which receives core support (P2C-HD041022) from the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Publicly available data onlyAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data are available online and can be accessed directly or through a web scraping routine that we provide at https://github.com/statsccpr/ind-cov-mort https://www.arcgis.com/apps/opsdashboard/index.html#/bda7594740fd40299423467b48e9ecf6 https://covid19.healthdata.org/ https://www.cdc.gov/nchs/nvss/vsrr/COVID19/index.htm